Nonalcoholic fatty liver disease associated with obesity: the potential of essential phospholipids
https://doi.org/10.21518/2079-701X-2016-4-116-122
Abstract
Today, the role and importance of the first contact medical specialist (physician or general practitioner) is increasing in the diagnosis and management of patients with obesity and nonalcoholic fatty liver disease today. The article discusses the diagnostic algorithm for obesity based on the AACE/ACE-2014 classification, and the potential of essential phospholipids in the therapeutic and prophylactic recommendations for patients with NAFLD associated with obesity.
Keywords
ожирение,
диагностический алгоритм,
неалкогольная жировая болезнь печени (НАЖБП),
лечебно-профилактические рекомендации,
эссенциальные фосфолипиды,
Гепагард Актив®,
obesity,
diagnostic algorithm,
non-alcoholic fatty liver disease (NAFLD),
therapeutic and preventive recommendations,
essential phospholipids,
Hepaguard Active®
References
1. Ng M, Fleming T, Robinson M. et aL Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study. Lancet, 2014 Aug 30, 384(9945): 766-81.
2. World Health Organization Media Centre. Obesity and overweight. Fact sheet N311 Updated January 2015. URL:http//www.who. int/mediacentre/factsheets/fs311/en/.
3. Fruhbeck G, Toplak H, Woodward E. et al. Obesity: The gateway to ill health - an EASO Position Statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts, 2013, 6(2): 117-20.
4. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff (Millwood), 2009 Sep-Oct, 28(5): 822-31.
5. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med, 2013 Mar, 273(3): 219-34.
6. World Health Organization Media Centre. Obesity and overweight. Fact sheet no Geneva: World Health Organization, 2013.
7. Defining Obesity. URL: http//asmbs.org/ patients/disease-of-obesity.
8. Garvey WT, Garber AJ, Mechanick JI et al. American association of clinical endocrinolo-gists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract., 2014 Sep, 20(9): 977-89.
9. Рекомендации по ведению больных c метаболическим синдромом. Клинические рекомендации. Министерство здравоохранения РФ. 2013. 42 с. URL:http//medpoiskpro.ru/ terapiya/klinicheskie-rekomendatsii-po-kardiologii-2013.
10. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени (Методические рекомендации). М.: ООО «Издательский дом «М-Вести», 2009. 20 с.
11. Драпкина О.М., Гацолаева Д.С., Ивашкин В.Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести, 2010, 2: 72-8.
12. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis, 2015, 239 : 192-202.
13. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obesepatients undergoing bariatric surgery. J. Hepatol., 206, 45(4) : 600-6.
14. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients, 2013, 5(5): 1544-60.
15. Chang E, Park CY, Park SW, Role of thiazolidinedi-ones, insulin sensitizers, in non-alcoholic fatty liver disease. J. Diabetes Investig., 2013, 4(6): 517-24.
16. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care, 2011, 34(5): 1139-44.
17. Трухан Д.И., Филимонов С.Н. Клиника, диагностика и лечение основных эндокринных и гематологических заболеваний. Новокузнецк: ООО «Полиграфист», 2015. 119 с.
18. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol., 2013, 167(4): 1109-17.
19. Guidelines for the management of patients with metabolic syndrome. Clinical guidelines. Ministry of Health of the RF. 2013. 42 p. URL:http://medpoiskpro.ru/terapiya/klinicheskierekomendatsii-po-kardiologii-2013.
20. Ivashkin V.T., Drapkina O.M., Shulpekova Y.O. Diagnosis and treatment of nonalcoholic fatty liver disease (Guidelines). М.: M-Vesti Publishing House OOO, 2009. 20 p.
21. Drapkina O.M., Gatsolayeva D.S., Ivashkin V.T. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Rossiyskie Meditsinskie Vesti, 2010 2: 72-8.
22. Trukhan D.I., Filimonov S.N. The clinical pattern, diagnosis and treatment of major endocrine and hematologic diseases. Novokuznetsk: Poligrafist, 2015. 119 p.
Review
For citations:
Trukhan DI. Nonalcoholic fatty liver disease associated with obesity: the potential of essential phospholipids. Meditsinskiy sovet = Medical Council. 2016;(4):116-122. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-116-122
Views:
851
Email this article 